Core Insights - Caleres completed the acquisition of Stuart Weitzman for $120.2 million in August 2023, which is expected to impact future earnings significantly [1][6] - The footwear brand reported net sales of $790.1 million for the 13 weeks ending November 1, 2025, marking a 6.6% increase from $740.9 million in the same period last year [1] - Direct-to-consumer sales represented approximately 71% of total net sales in the reported quarter [1] Financial Performance - Gross profit for Caleres increased to $329.9 million in Q3, up from $326.9 million in the prior year, but gross margin decreased by 230 basis points to 41.8% [2] - SG&A expenses rose to $311.3 million, accounting for 39.4% of net sales, an increase of 310 basis points from the previous year, largely due to costs associated with Stuart Weitzman [3] - GAAP net earnings fell sharply to $2.4 million, or $0.07 per diluted share, compared to $41.4 million, or $1.19 per diluted share, in the prior-year period [4] Inventory and Outlook - Inventory at the end of the quarter was $678.2 million, an increase of $92 million year-over-year, with Stuart Weitzman contributing $77 million to this total [5] - For the remainder of fiscal 2025, the company anticipates ongoing tariff headwinds affecting gross margin and expects GAAP loss per diluted share between $0.13 and $0.18, with adjusted earnings per diluted share between $0.55 and $0.60, factoring in dilution from Stuart Weitzman [6] - The company plans to transition the Stuart Weitzman business to its systems and address aged inventory, aiming for long-term growth and profitability starting in fiscal 2026 [7]

Core Insights - Vaso Corporation's shares have declined 4.3% since the earnings report for Q2 2025, underperforming the S&P 500 Index, which lost 1.1% during the same period [1] - The company reported a revenue decrease of 1.3% year-over-year, resulting in a net loss of $0.2 million compared to a net income of $1.2 million in the previous year [2] Revenue Breakdown - Professional sales services revenue fell 4% to $8.7 million, primarily due to lower diagnostic imaging equipment deliveries from GE HealthCare [3] - The IT segment saw a slight increase of 0.9% to $10.7 million, driven by stronger network services, while the equipment segment remained nearly flat at $0.5 million, up 0.8% [3] Profitability Metrics - Gross profit decreased by 2.9% to $11.8 million, with a margin of 59%, down from 60% a year ago [4] - Selling, general and administrative (SG&A) expenses surged 11.2% to $12.1 million, contributing to an operating loss of $0.4 million compared to an operating income of $0.9 million in the prior year [5] Cash Flow and EBITDA - Adjusted EBITDA fell to a loss of $0.3 million from a positive $1.2 million in the previous year, while cash flow from operations improved to $6.2 million from $1.7 million [6] Management Commentary - Management attributed revenue decline to fewer GE HealthCare imaging equipment deliveries, with deferred commission revenue increasing to $38.1 million from $31.7 million [7] - Monthly recurring revenue in the IT segment represented 89% of segment revenues, up from 83% in the prior year [7] Operating Expenses - Operating expenses rose 9.5% to $12.2 million, mainly due to higher salesforce compensation and investor relations costs [8] Factors Influencing Performance - The quarterly loss was driven by contracting gross profit and rising SG&A expenses, with IT division margins narrowing due to a shift towards lower-margin network services [9] - Interest income decreased due to lower interest rates, although tax expenses declined, partially offsetting losses [10] Future Outlook - Vaso did not provide formal guidance for the remainder of 2025 but expressed confidence in ongoing IT recurring revenues and a strong deferred revenue balance [11] - The company remains bound by its sales representation agreement with GE HealthCare through 2026 and drew a short-term loan in China to support working capital needs [12]